CARB-X News

• 02.06.2019  |  CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram-negative superbugs

  Recida’s new LpxC inhibitor is a potential treatment for multidrug-resistant Enterobacteriaceae and P. aeruginosa infections

  Full Story

• 02.04.2019  |  CARB-X funds Polyphor to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs

  CARB-X, a Boston University global partnership, is awarding Polyphor (SIX: POLN) of Allschwil, Switzerland, up to $2.6 million in non-dilutive funding with the possibility of $3.0 million more if certain project milestones are met, to develop a novel antibiotic with a novel mode of action to treat serious infections caused by Gram-negative ESKAPE pathogens.

  Full Story

• 01.03.2019  |  CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa

  CARB-X is awarding Forge Therapeutics of San Diego, CA, USA, up to $5.7 million in non-dilutive funding, with the possibility of up to $5.4 million more if certain project milestones are met, to develop a novel antibiotic to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa. This is Forge’s second project to earn CARB-X support

  Full Story